The leading cause of death in the USA, heart failure most often represents slow progression of multi-factorial disease, diagnosed as """"""""idiopathic"""""""" dilated cardiomyopathy. While the prognosis of treated heart failure continues to be poorer than for most malignancies, there is substantial patient variability in incidence and clinical course that implies the existence of unknown modifiers. We hypothesize that inter-individual differences in susceptibility to and progression of heart failure result from poorly defined environmental and genetic stressors. We have previously defined variations (polymorphisms or mutations) in critical cardiac genes that, alone or in combination, modify or cause heart failure. As some of these variants cluster in distinct ethnic groups, they may constitute a mechanism for known differences in prevalence and outcome of heart failure among ethnic minorities. The five Projects of this SCCOR will examine naturally-occurring genetic or transcriptional events within cardiac adrenergic signaling pathways. Project 1 (Liggett) will extend his highly successful survey of and a2-adrenergic receptor polymorphisms in heart failure, focusing on combinatorial effects of different receptor haplotypes on myocardial contractility. Related Project 2 (Dorn) will examine the roles of novel variants of alpha-1-adrenergic receptors and cardiac-expressed RGS and GRK proteins on cardiac hypertrophy and its progression to heart failure. Project 3 (Kranias) follows up her recent description of a phospholamban mutant that causes lethal familial cardiomyopathy with clinical and basic investigations of newly discovered polymorphisms for phospholamban and phosphatase inhibitor 1 (PPI1) as genetic risk factors for heart failure. Related Project 4 (Molkentin) will define the interactions of PPI1 with protein kinase Cot, itself transcriptionally upregulated in heart failure, and delineate their combined effects on myocardial responsiveness to adrenergic agonists. Project 5 (Robbins) will use transgenesis in human-like rabbit hearts to establish the effects of altered alpha/beta-myosin heavy chain expression on cardiac responses to environmental stressors. Studies will be performed in human subjects, genetically modified animal models, and cultured cells, and are supported by Cores for Genomics, Biostatistics, Stem Cell Manipulation, and Clinical Research Skills Development. We believe this thematically linked, multidisciplinary Center will continue to break new ground in understanding the pathogenesis and optimal management of heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL077101-05
Application #
7564000
Study Section
Special Emphasis Panel (ZHL1-CSR-S (M1))
Program Officer
Adhikari, Bishow B
Project Start
2005-02-22
Project End
2011-12-31
Budget Start
2009-01-01
Budget End
2011-12-31
Support Year
5
Fiscal Year
2009
Total Cost
$3,958,730
Indirect Cost
Name
University of Cincinnati
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Kim, Ka Eul; Tae, Hyun-Jin; Natalia, Petrashevskaya et al. (2016) Cardiac physiologic regulation of sub-type specific adrenergic receptors in transgenic mice overexpressing ?1- and ?2-adrenergic receptors. Clin Exp Emerg Med 3:175-180
Karch, Jason; Molkentin, Jeffery D (2015) Regulated necrotic cell death: the passive aggressive side of Bax and Bak. Circ Res 116:1800-9
Gupta, Manish K; Gulick, James; Liu, Ruijie et al. (2014) Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes. Circ Res 115:721-9
Sandri, Marco; Robbins, Jeffrey (2014) Proteotoxicity: an underappreciated pathology in cardiac disease. J Mol Cell Cardiol 71:3-10
Holmes, Michael V; Exeter, Holly J; Folkersen, Lasse et al. (2014) Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet 7:144-50
Correll, Robert N; Eder, Petra; Burr, Adam R et al. (2014) Overexpression of the Na+/K+ ATPase ?2 but not ?1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 114:249-256
van Berlo, Jop H; Kanisicak, Onur; Maillet, Marjorie et al. (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337-41
Gupta, Manish K; Robbins, Jeffrey (2014) Post-translational control of cardiac hemodynamics through myosin binding protein C. Pflugers Arch 466:231-6
Alves, Marco L; Dias, Fernando A L; Gaffin, Robert D et al. (2014) Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet 7:132-143
Lam, Chi Keung; Zhao, Wen; Cai, Wenfeng et al. (2013) Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90. Circ Res 112:79-89

Showing the most recent 10 out of 134 publications